Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients

Transplantation

Volumn 81, Issue 7, 2006, Pages 1004-1009

  Augustine, Joshua J ^a,b   Chang, Peter C ^a   Knauss, Thomas C ^a   Aeder, Mark I ^a   Bodziak, Kenneth A ^a   Schulak, James A ^a   Hricik, Donald E ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b LS 8117 ^*  (United States)

Author keywords

Kidney transplantation; Mycophenolate mofefil; Sirolimus

Indexed keywords

CORTICOSTEROID; CREATININE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; VIREMIA;

DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; SIROLIMUS; TACROLIMUS;

EID: 33646372477     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000202880.78509.b4     Document Type: Article

References (27)

1. Andoh TF, Lindsley J, Franceschini N, Bennett WM. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996; 62: 311.
2. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059.
3. Kahan BD. Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc 2003; 35(S3A): 37S.
4. Masterson R, Leikis M, Perkovic V, et al. Sirolimus: a single center experience in combination with calcineurin inhibitors. Transplant Proc 2003; 35(S3): 99S.
5. Formica RN, Lorber KM, Friedman AL, et al. Sirolimus-based immunosuppression with reduce dose cyclosporine or tacrolimus after renal transplantation. Transplant Proc 2003; 35(S3A): 95S.
6. Chueh SJ, Kahan BD. Clinical application of sirolimus in renal transplantation: an update. Transpl Int 2005; 18: 261.
7. Velosa JA, Larson TS, Gloor JM, Stegall MD. Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety. Am J Kidney Dis 2001; 38(S2): S3.
8. Gonwa TA, Hricik DE, Brinker K, et al. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74: 1560.
9. Stallone G, Di Paolo S, Schena A, et al. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 2003; 75: 998.
10. Mota A, Arias M, Taskinen EI, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953.
11. Lo A, Egidi MF, Gaber LW, Gaber AO. Observations on the use of sirolimus and tacrolimus in high-risk renal transplant recipients. Transplant Proc 2003; 35(3A): 105S.
12. McAlister VC, Gao Z, Peltekian K, et al. Sirolimus-tacrolimus combination immunosuppression [letter]. Lancet 2000; 355: 276.
13. Hricik DE, Anton HA, Knauss TC, et al. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. Transplantation 2002; 74: 189.
14. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005; 5: 2273.
15. Kaplan B, Schold J, Srinivas T, et al. Effect of sirolimus withdrawal in patients with deteriorating renal function. Am J Transplant 2004; 4: 1709.
16. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461.
17. Andoh TK, Burdmann EA, Fransechini N, et al. Comparison of acute rapamycin nephrotoxicity with cyclosporine and TAC506. Kidney Int 1996; 50: 1110.
18. Shihab FS, Bennett WM, Yi H, et al. Sirolimus increases transforming growth factor-β1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004; 65: 1262.
19. Ninova D, Covarrubias M, Rea DJ, et al. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-β1 and α-smooth muscle actin. Transplantation 2004; 78: 338.
20. Khanna AK. Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. Transplantation 2000; 70: 690.
21. Oliveira JGG, Xavier P, Sampaio SM, et al. Compared to mycophenolate mofetil, rapamycin induces significant changes on growth factors and growth factor receptors in the early days postkidney transplantation. Transplantation 2002; 73: 915.
22. Shimizu H, Takahashi M, Takeda SI, et al. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation 2004; 77: 1661.
23. Shihab FS, Bennett WM, Yi H, et al. Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity. Am J Transplant 2003; 3: 1550.
24. Shihab FS, Bennett WM, Yi H, et al. Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-β1. Transplantation 2004; 77: 683.
25. Morales JM, Wramner L, Kreis H, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436.
26. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070.
27. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776.